Sarepta (SRPT) rallies 6% AH.
The company is out with data through week 120 in the Phase 2b eteplirsen extension study.
Summary: Patients in 30mg and 50mg cohorts able to perform the 6-minute walk test "experienced a decline of 13.9 meters, or less than 5%, from baseline in walking ability;" treatment benefit is a statistically significant 64.9 meters.
SRPT says it "now [has] more than two years of data with eteplirsen on the 6-minute walk test, the most accepted clinical outcome measure in DMD which demonstrates walking stability that [the company] believes would not be expected based on the natural history of this disease over the same time period." (PR)